Dr. Galsky on Biomarkers for Satraplatin in mCRPC
Matthew D. Galsky, MD, associate professor, medicine, hematology and medical oncology, assistant professor, urology, The Mount Sinai Hospital, discusses a biomarker development trial of satraplatin in patients with metastatic castrate-resistant prostate cancer (mCRPC).
Satraplatin is an oral platinum drug that has been tested in phase III trial but did not show survival benefit and was not approved by the FDA. Galsky says that satraplatin represents a clear example of a drug that has objective evidence that it works and inhibits tumor growth but did not work in enough patients.
The question remains as to whether it’s possible to identify which patients will respond to satraplatin. In this trial, about half of the patients saw benefit with satraplatin, consistent with phase III results, and now tumor samples are being analyzed.